The top 10 medical disruptors of 2018


4. The unprecedented reduction of LDL cholesterol


[Image from]

There is a new class of LDL cholesterol lowering drugs that are expected to be disruptors in the next year. The new drugs are expected to lower cholesterol to unprecedented levels.

When taken with a Statin cholesterol lowering drug, the new class of drugs is expected to lower cholesterol levels by 75%.

The small interfering RNA therapy to lower LDL was also a new innovation in 2017. They are given twice a year instead of monthly or weekly like other treatments.

Dr. Leslie Cho of the Heart & Vascular Institute at the Cleveland Clinic suggests that we will continue to see a new class of agents to lower LDL levels in 2018.

Statin drugs could one day be an over-the-counter drug, said Cho.

Next >>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11


  1. Very promising disruptions in Healthcare. Will be interested as an incubator to closely track the development of ideas of healthcare startups.

Speak Your Mind